At the time of writing, Bicara Therapeutics Inc [BCAX] stock is trading at $15.75, up 5.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCAX shares have gain 27.43% over the last week, with a monthly amount glided 28.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on February 06, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $31. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 06, 2024, and set its price target to $42. On November 05, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $48 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Stifel initiated its recommendation with a Buy and recommended $47 as its price target on October 08, 2024. Morgan Stanley started tracking with a Overweight rating for this stock on October 08, 2024, and assigned it a price target of $35. In a note dated October 08, 2024, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Bicara Therapeutics Inc fluctuated between $11.10 and $28.09. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $15.75 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.63 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.72 points at the first support level, and at 13.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.30, and for the 2nd resistance point, it is at 16.86.
Ratios To Look Out For
It is important to note that Bicara Therapeutics Inc [NASDAQ:BCAX] has a current ratio of 36.01. In addition, the Quick Ratio stands at 36.01 and the Cash Ratio stands at 35.96.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Sep 16 ’24 when 1.83 million shares were purchased. Possible Members of 10% Group, Flynn James E completed a deal on Sep 17 ’24 to buy 70000.0 shares.
